Patents Assigned to Angioblast Systems, Inc.
-
Patent number: 9815896Abstract: The present invention relates to a monoclonal antibody designated STRO-4 which specifically binds human and ovine HSP-90beta and its use for enriching multipotential cells such as mesenchymal precursor cells (MPCs).Type: GrantFiled: July 9, 2015Date of Patent: November 14, 2017Assignee: ANGIOBLAST SYSTEMS, INCInventors: Stan Gronthos, Andrew Christopher William Zannettino
-
Patent number: 9783617Abstract: The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells.Type: GrantFiled: May 27, 2016Date of Patent: October 10, 2017Assignee: ANGIOBLAST SYSTEMS, INC.Inventors: Stan Gronthos, Andrew Christopher William Zannettino, John Paul Simmons
-
Publication number: 20170204373Abstract: Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as MUC 18, VCAM-1 and STRO-1bri. The perivascular mesenchymal precursor cell is multipotential and is shown to form, vascular tissue, as well as bone marrow dentin and pulp. A method of enriching using cell sorting based on these markers is also described.Type: ApplicationFiled: June 23, 2015Publication date: July 20, 2017Applicant: ANGIOBLAST SYSTEMS, INC.Inventors: Stan Gronthos, Andrew Zannettino, Songtao Shi
-
Publication number: 20150368614Abstract: Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as MUC 18, VCAM-1 and STRO-1bri. The perivascular mesenchymal precursor cell is multipotential and is shown to form, vascular tissue, as well as bone marrow dentin and pulp. A method of enriching using cell sorting based on these markers is also described.Type: ApplicationFiled: June 23, 2015Publication date: December 24, 2015Applicant: ANGIOBLAST SYSTEMS, INC.Inventors: Stan Gronthos, Andrew Zannettino, Songtao Shi
-
Publication number: 20150267171Abstract: The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells.Type: ApplicationFiled: February 13, 2015Publication date: September 24, 2015Applicant: ANGIOBLAST SYSTEMS, INC.Inventors: Stan Gronthos, Andrew Christopher William Zannettino, John Paul Simmons
-
Publication number: 20150072422Abstract: The present invention relates to methods of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC) and/or progeny derived therefrom in vitro or in vivo comprising exposing the MPC or progeny to SDF-1 or analog thereof. The invention also relates to compositions comprising isolated MPCs or progeny derived therefrom and SDF-1 or analogues thereof. The present invention also relates to using such methods and compositions for ex vivo or in vivo bone formation in mammals.Type: ApplicationFiled: August 27, 2014Publication date: March 12, 2015Applicant: ANGIOBLAST SYSTEMS, INC.Inventors: Stan Gronthos, Andrew Christopher William Zannettino
-
Patent number: 8158118Abstract: A method of enriching mesenchymal precursor sells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilizing MACS recognizing expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilizing two color FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1.Type: GrantFiled: June 29, 2005Date of Patent: April 17, 2012Assignee: Angioblast Systems, Inc.Inventors: Paul Simmons, Andrew Zannettino, Stan Gronthos
-
Patent number: 8062675Abstract: A method of enriching mesenchymal precursor cells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilising MACS recognising expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilising two colour FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1.Type: GrantFiled: February 17, 2010Date of Patent: November 22, 2011Assignee: Angioblast Systems, Inc.Inventors: Stan Gronthos, Andrew Zannettino, Paul Simmons
-
Patent number: 7947266Abstract: Mesenchymal precursors cells have been isolated from perivascular niches from a range of tissues utilizing a perivascular marker. A new mesenchymal precursor cell phenotype is described characterized by the presence of the perivascular marker 3G5, and preferably also alpha smooth muscle actin together with early developmental markers such as MUC 18, VCAM-1 and STRO-1bri. The perivascular mesenchymal precursor cell is multipotential and is shown to form, vascular tissue, as well as bone marrow dentin and pulp. A method of enriching using cell sorting based on these markers is also described.Type: GrantFiled: March 29, 2004Date of Patent: May 24, 2011Assignee: Angioblast Systems Inc.Inventors: Stan Gronthos, Andrew Zannettino, Songtao Shi
-
Publication number: 20100111910Abstract: The present invention relates to methods of treating or preventing angiogenesis-related diseases by the administration of stem cells and/or progeny cells thereof.Type: ApplicationFiled: July 12, 2007Publication date: May 6, 2010Applicant: ANGIOBLAST SYSTEMS, INC.Inventor: Piroska Elizabeth Rakoczy
-
Patent number: 7670628Abstract: A method of enriching mesenchymal precursor cells including the step of enriching for cells based on at least two markers. The markers may be either i) the presence of markers specific for mesenchymal precursor cells, ii) the absence of markers specific for differentiated mesenchymal cells, or iii) expression levels of markers specific for mesenchymal precursor cells. The method may include a first solid phase sorting step utilizing MACS recognizing expression of the antigen to the STRO-1 Mab, followed by a second sorting step utilizing two colour FACS to screen for the presence of high level STRO-1 antigen expression as well as the expression of VCAM-1.Type: GrantFiled: March 29, 2004Date of Patent: March 2, 2010Assignee: Angioblast Systems, Inc.Inventors: Paul Simmons, Andrew Zannettino, Stan Gronthos
-
Publication number: 20080260694Abstract: The invention relates to multipotential expanded mesenchymal precursor progeny (MEMP's), characterised by the early developmental markers STRO-1bri and ALP. The present invention also relates to methods for producing MEMP's and to uses of MEMP's for therapeutic applications.Type: ApplicationFiled: September 26, 2005Publication date: October 23, 2008Applicant: ANGIOBLAST SYSTEMS, INC.Inventors: Stan Gronthos, Andrew Christopher William Zannettino